Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR‐ABL inhibitor use by using an adverse drug event reporting database
Naoto Okada(Yamaguchi University Hospital), Keisuke Ishizawa(Tokushima University Hospital), Takahiro Niimura(Tokushima University), Hirofumi Hamano(Tokushima University Hospital), Mitsuhiro Goda(Okayama University), Masaki Imanishi(Tokushima University Hospital), Masayuki Chuma(Nihon University), Kenshi Takechi(Matsuyama University), Shunsuke Ishida(The University of Osaka), Yoshito Zamami(Tokushima University Hospital)
Cited by 23
Related Papers
Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis
|JAMA Oncology|2019|134
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
|Clinical Therapeutics|2018|99
Royal Jelly Ameliorates Insulin Resistance in Fructose-Drinking Rats
|Biological and Pharmaceutical Bulletin|2008|88
Trends in Polypharmacy in Japan: A Nationwide Retrospective Study
|Journal of the American Geriatrics Society|2018|81
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent
|Bioorganic & Medicinal Chemistry|2008|75